Cooper's Pivot: The Strategic Review Moves From Study to Sale
Litigation cleared, CooperSurgical interest formalized — and the capital allocation story changes with it.
COO · Earnings Call · 2026-06-04
A Decade of Defense Reversed
The most consequential change at The Cooper Companies this quarter is not in the financials — it is in the strategy. After years of publicly defending the combination of CooperVision and CooperSurgical, management has shifted to actively advancing a potential sale of the surgical business. The trigger was clearing the overhang of litigation stemming from the December 2023 embryo culture media recall.
We've now reached settlements with substantially all of the claimants in this case... With that done, we are now actively advancing discussions with multiple parties that have submitted significant indications of interest in CooperSurgical.
This is a genuine reversal from prior posture. On previous calls, the combination was defended for its flexibility and back-office synergies; now the calculus explicitly favors transacting. “We have a lot of cash flow as a combined business... But I also look at the market right now... and we're in a position... where there's a good argument that private investors are willing to pay a premium price over the public markets. If that is the case... then we're going to do what's best for our shareholders.” — Albert White · 2026-06-04
The appearance of litigation and settlement as top momentum movers this quarter, alongside entire business vaulting to rank one, underscores how singular the strategic review has become as a catalyst.
The Settlement That Unlocked Everything
The litigation charge is the headline number. “The net impact to resolve outstanding claims was $271.6 million, consisting of $324.1 million of accrued settlement, partially offset by $52.5 million of insurance recoveries.” — Brian Andrews · 2026-06-04 That drove operating income to −$48M in Q2 2026, and swung the reported net loss to −$78M, despite record revenue of $1.08B growing 8%. Management excluded the charge from non-GAAP EPS, which rose 26% to $1.21 on the strength of the underlying operations.
On buyer interest, Al White was candid: “We received... significant interest in the entire business and in pieces of the business, both. But... there's a sufficient number of parties that have given indications of interest that are on the entire business, that's how we're moving forward.” — Albert White · 2026-06-04 The phrasing matters — a whole-business sale avoids the integration complexity of splitting fertility from medical devices, and it broadens the pool of likely acquirers (private equity, strategic buyers). Timing is now the question; the company expects a more definitive update "soon," possibly before the next earnings call.
Asia Pacific: The Persistent Drag on an Otherwise Healthy Portfolio
But the quarter is not just about the strategic review. Operational softness continues in Asia Pacific, which dragged CooperVision guidance down roughly a point. Al White cut through the detail: “It's Asia Pac and it's market-based... Consumer weakness. We really see that not in every market, but we see it in Japan, and we see it in China.” — Albert White · 2026-06-04 The hydrogel products rationalization continues to pressure results, though the impact is gradually diminishing.
This is a contrast to the encouraging developments elsewhere — MyDay MiSight in Europe is performing "extremely well," MiSight grew 24% to $32M, and the premium product mix in the Americas and EMEA remains strong. The regional divergence is stark: Americas +7%, EMEA +6%, Asia Pac −6%.
Capital Allocation and the Path Forward
On buybacks, management signaled a clear shift after a quiet quarter. “We started purchasing a few shares back... essentially a few days after we reported earnings but then took a... conservative position... We do not have those restrictions now and would anticipate exiting this call being much more aggressive on share buybacks going forward.” — Albert White · 2026-06-04 If a CooperSurgical sale closes, the proceeds are earmarked largely for repurchases: "the vast majority of them are certainly used for buybacks."
Free cash flow generation remains the backbone — $96M of free cash flow helped trim net debt to $2.3B, an improvement that supports either buyback aggression or shareholder returns. The company also raised its 2026 free cash flow outlook to ~$650M, excluding litigation payouts, and reiterated the $2.2B cumulative 2026-2028 target — now explicitly inclusive of expected litigation outflows.
There are two residual catalysts on the revenue side. The first is refunds from tariffs — guidance assumes ~$22M of tariff costs but none of the potential refunds, which could add as much as $15M of upside. The second is the Asia Pacific reset, which management expects to align with market growth by Q4. Combined, the setup is one of a company finally removing the litigation overhang, monetizing a strategic asset at what management believes is an attractive private-market premium, and redeploying the proceeds into buybacks — with the operational story in the Americas and EMEA still growing.
The risk is execution: the strategic review adds uncertainty even as it adds optionality, and Asia Pacific could continue to disappoint. But for a stock trading 33% below its 2021 peak and at a 3.3x price-to-revenue valuation, the re-rating potential from a clean divestiture and disciplined buybacks is the real story here.